

Original Article

Influence of variants of the *drosha*, *mir499a*, and *mir938* genes on susceptibility to acute lymphoblastic leukemia in an admixed population from the brazilian amazon

Tatiane Piedade de Souza², Darlen Cardoso de Carvalho¹, Alayde Viera Wanderley^{1,4}, Sweny Marinho Fernandes^{1,4}, Juliana Carla Gomes Rodrigues¹, Amanda Cohen-Paes¹, Marianne Rodrigues Fernandes¹, Fernando Augusto Rodrigues Mello Junior⁵, Lucas Favacho Pastana¹, Lui Wallacy Morikawa Souza Vinagre¹, Artur Luiz da Costa Silva³, Paulo Pimentel de Assumpção¹, Sidney Santos^{1,2}, André Salim Khayat¹, Ney Pereira Carneiro dos Santos^{1,2}

¹Research Center of Oncology, Federal University of Pará, Belém, Pará, PA, Brazil; ²Laboratory of Human and Medical Genetics, Institute of Biological Sciences, Belém, Pará, PA, Brazil; ³PTC Laboratory of Biological Engineering-Guamá, Belém, Pará, PA, Brazil; ⁴Otávio Lobo Children's Cancer Hospital-HOIOL-Belém, Pará, PA, Brazil; ⁵Molecular Biology Laboratory of The Ophir Loyola Hospital-HOL-Belém, Pará, PA, Brazil

Received August 28, 2020; Accepted October 25, 2020; Epub December 15, 2020; Published December 30, 2020

Abstract: Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer in children. Polymorphisms that alter the normal function of the microRNAs involved in the development of ALL have been widely investigated, although published data on these polymorphisms in admixed populations are scarce. We investigated the role of 10 polymorphisms in the microRNA and protein-coding genes of the microRNA synthesis complex in susceptibility to pediatric B-cell ALL. The study includes 100 pediatric ALL patients and 180 healthy individuals. The statistical analyses were run in SPSS v.25.0. In the case of the microRNA synthesizing genes, a significant pattern was found in only one gene, that is, the rs3805500 polymorphism of *DROSHA*, in which the homozygous mutant (AA) genotype was associated with a threefold increase in the risk of developing ALL when compared to other genotypes (P=0.004, OR=2.913, CI=1.415-5.998). In the microRNA coding genes, the homozygous mutant rs3746444 genotype of the *MIR499A* gene was associated with a 17-fold increase in the risk of development of ALL (P<0.001, OR=17.797, CI=5.55-57.016). A protective effect against the development of ALL was also observed in the carriers of the wild homozygous rs2505901 genotype in the *MIR938* gene. Our findings highlight the potential of these polymorphisms in the genes involving in the coding of microRNAs for the evaluation of the risk of contracting ALL in the population of the Brazilian Amazon region. These findings contribute to a more complete understanding of the complex etiology of ALL.

Keywords: Acute lymphoblastic leukemia, microRNAs, single nucleotide polymorphism, susceptibility

Introduction

Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer in children and adolescents of up to 19 years of age, representing 28% of all malignancies in this age group and 75% of all cases of leukemia [1-3]. The etiology of ALL is considered to be multifactorial, involving both environmental and genetic factors, which have been investigated extensively. These factors include exposure to

carcinogens, as well as chromosomal and molecular alterations [4, 5]. In particular, many single nucleotide polymorphisms (SNPs) in key genes of the regulatory pathways have been ascribed a fundamental role in the development of ALL [6].

The investigation of the SNPs found in the microRNA genes has emerged as a promising new field of genomic research. The principal function of these molecules is to regulate gene

expression via post-transcriptional silencing, the cleaving of messenger RNAs (mRNA) or inhibiting the initiation of translation through base pairing between the microRNA and its mRNA target [7]. The presence of SNPs in microRNA genes or the protein-coding genes involved in the synthesis of the microRNAs may affect their correct functioning, resulting in impacts on gene regulation processes [8]. Despite the important regulatory potential of these polymorphisms, few studies have focused on the influence of the SNPs located in non-coding genomic regions. In addition, evidence on the occurrence of these polymorphisms in populations with high levels of miscegenation, such as that of the Brazilian Amazon region, is particularly scarce. Given this, the present study investigated the role of 10 polymorphisms of the microRNA and microRNA synthesis genes in the susceptibility of pediatric patients from the Brazilian Amazon region to B-cell ALL.

Material and methods

Patients and controls

The case group of the present study included 100 patients diagnosed with B-cell ALL by immunophenotyping and/or molecular analysis. All these individuals were in treatment at the Otávio Lobo Hospital in Belém, a reference center for the treatment of pediatric cancer in the northern region of Brazil. The patients included in the study were between 1 and 18 years old. Recurrent patients or those with comorbidities were not included in the group. The control group consisted of 180 individuals with no diagnosis for B-cell ALL or any other type of cancer. None of these individuals were related to any of the patients in the case group, and they were all over the peak risk age for the development of ALL.

Ethical aspects

This study was approved by the Research Ethics Committee of the Research Center of Oncology of the Federal University of Pará (CAAE number 11433019.5.0000.5634). All participants (or their legal guardians) signed a term of informed consent authorizing the collection of samples and data.

Selection of the study polymorphisms

The SNPs selected for the present study were chosen due to their known association with susceptibility to ALL and different types of cancer, based on the published data. The references of the journal articles used for the selection of the polymorphisms are listed in the [Table S1](#) [38-48]. A total of 10 polymorphisms were selected, seven in microRNA genes and three in the protein-coding genes essential to the synthesis of microRNAs: rs-636832 (*AGO1*), rs10035440 e rs3805500 (*DROSHA*), rs213210 and rs107822 (*MIR-219-1*), rs2910164 (*MIR146a*), rs12894467 (*MIR300*), rs3746444 (*MIR499a*), rs4919510 (*MIR608*), and rs2505901 (*MIR938*).

Extraction and quantification of the DNA

The DNA was extracted from peripheral blood using a commercial DNA extraction kit (Biopur Mini Spin Plus-250 extraction kit, Biopur, Brazil). The concentration of the genetic material was quantified in a NanoDrop 1000 spectrophotometer (Scientific Term NanoDrop 1000; NanoDrop Technologies Wilmington, DE).

Genotyping of polymorphisms

The 10 polymorphisms were genotyped by allelic discrimination using the TaqMan Open-Array Genotyping technology with a set of 32 customized assays, which were run in a QuantStudio™ 12K Flex Real-Time PCR system (Applied Biosystems, Life Technologies, Carlsbad, USA), according to the manufacturer's protocol. This method is based on real-time Polymerase Chain Reaction (qPCR). The quality of the readings of the genotypes and other data were analyzed in the TaqMan Genotyper software.

Quality control

To ensure an adequate level of accuracy, polymorphisms were only included in the present study if they satisfied three criteria: (i) MAF \geq 1%; (ii) genotyping rate \geq 80%, and (iii) were in Hardy-Weinberg (HWE). The HWE was performed using the Arlequin software (v.3.5.1.2). The significance of the HWE test was adjusted for multiple comparisons by the Bonferroni

Polymorphisms in microRNA genes and the ALL risk

Table 1. Primers used for RT-PCR in the chromosomal fusion analysis

Cromossomic Fusion	Genes	Primer (5'-3')
t(1;19)(q23;p13)	E2A	CTACTCCCGGATCACTCAA
	PBX1	AGGCTTCATTCTGTGGCAGT
t(4;11)(q21;q23)	MLL	CGCCCAAGTATCCCTGTAAA
	AF4	GAGCATGGATGACGTTCCCTT
t(9;22)(q34;q11)	BCR	TCGCAGAACTCGCAACAGT
	ABL	ACACCATTCCCATTGTGAT
t(12;21)(p13;q22)	TEL	TCTCTCATCGGGAAGACCTG
	AML1	TGCGGTAGCATTCTCAGC
del(1)(p32;p32)	SIL	TCCTACCCTGCAAACAGACC
	TAL1	AGGCGGAGGATCTCATTCTT

Table 2. Demographic parameters for the case (patients with B-cell ALL) and control groups analyzed in the present study

Variable	Case (100)	Control (180)	p-value
Sex (M/F)	60/40	53/127	<0.001 ^a
Age*	5.53 ± 3.991	65.97 ± 16.021	<0.001 ^b
<i>Genetic ancestry*</i>			
European	0.429 ± 0.133	0.454 ± 0.170	0.189 ^c
African	0.203 ± 0.089	0.241 ± 0.138	0.213 ^c
Amerindian	0.361 ± 0.154	0.304 ± 0.149	0.004 ^c

^aChi-square, ^bStudent's t, ^cMann-Whitney U. *Mean ± eStandard Deviation.

method ($P \leq 0.001$), and the HWE values are shown in the [Table S2](#). As all 10 of the polymorphisms selected for the present study satisfied these criteria, they were all included in the association analyses ([Table S2](#)).

Fusion analysis by extraction of the RNA and the reverse transcriptase-polymerase chain reaction (RT-PCR)

For the cytogenetic analysis of the BCR-ABL, ETV6-RUNX1, MLL-AF4, SIL-TAL and E2A-PBX1 fusions, blood samples were collected from 84 patients via venipuncture and stored in EDTA. Ficoll Histopaque® (Sigma-Aldrich, USA) was added to the samples for the separation of the lymphocytes, following the manufacturer's instructions. The ARNsy MiniKit (Qiagen, USA) and High Capacity cDNA Reverse Transcription kits (Applied Biosystems, USA) were used to extract RNA and convert cDNA, respectively, both according to the manufacturers' protocols. A multiplex RT-PCR reaction was run using The Master Mix kit (Promega,

USA) with the primers designed specifically for the five fusions mentioned above, also following the manufacturer's instructions. The primers used for RT-PCR are listed in [Table 1](#).

Analysis of genomic ancestry

The genomic ancestry of the participants was analyzed following Santos et al. (2010) and Ramos et al. (2016), using a set of 61 Ancestry Informative Markers (AIMs). The individual and global proportions of European, Amerindian, and African genetic ancestry were estimated using STRUCTURE v.2.3.4 [9-11].

Statistical analyses

The Chi-square test was applied for the pairwise comparisons of the categorical variables between the case and control groups, while the quantitative variables were compared using Student's *t*. The multivariate analyses considered the sex of the participants and Amerindian ancestry as confounding variables. The Mann-Whitney test was used to compare the estimates of genetic ancestry between the groups. All statistical analyses were run in SPSS v.25.0 (SPSS, Chicago, IL, USA), considering a $P \leq 0.05$ significance level.

Results

Significant differences were found between the case (ALL) and control group ages, sex ratio, and genomic ancestry ([Table 2](#)). The mean age of the case group was significantly lower than that of the control group ($P < 0.001$) and the sex ratios also varied significantly between groups ($P < 0.001$), with a predominance of males in the case group and of females in the control group.

The genomic makeup of the case group was dominated by European ancestry (43%), followed by the Amerindian (36%) and African (20%) components. While the control group presented a similar makeup (European-45%, Amerindian-30%, African-24%), its Amerindian ancestry was significantly lower ($P = 0.004$) than that of the case group. Given the observed variation, both sex and Amerindian ancestry




Figure 1. Distribution of the B-cell ALL subtypes in the study patients of the case group.

were controlled for in the analyses of the potential association between the polymorphisms and susceptibility to ALL.

The distribution of the B-cell ALL subtypes, based on the occurrence of the chromosomal fusions analyzed here, is shown in **Figure 1**. The most frequent fusions were E2A-PBX1 (21.42%) and BCR-ABL (14.30%), followed by ETV6-RUNX1 (7.14%), MLL-AF4 (2.38%), and SIL-TAL (1.19%).

Three SNPs were investigated further in the case of the genes involved in the synthesis of microRNAs, and a significant pattern was observed in the case of the recessive model (AA vs. GG + GA) of the rs3805500 variant of the *DROSHA* gene (**Table 3**). The mutant homozygote (AA) genotype of this gene was associated with a threefold increase in the risk of developing ALL ($P=0.004$, $OR=2.913$, $CI=1.415-5.998$).

Seven variants of the microRNA genes were analyzed, of which, two were related signifi-

cantly to the susceptibility of the carrier to ALL (**Table 3**)-MIR499A (rs3746444) and MIR938 (rs2505901). The mutant homozygote rs3746444 (GG) genotype was associated with a 17-fold increase in the risk of developing ALL ($P<0.001$, $OR=17.797$, $CI=5.55-57.016$). By contrast, the wild homozygous rs2505901 (CC) genotype was associated with a lower risk for the development of ALL, apparently conferring a protective effect ($P=0.013$, $OR=0.359$, $CI=0.160-0.805$).

Discussion

The population of Brazil is one of the world's most genetically heterogeneous, and the pediatric ALL patients analyzed in the present study had a high level of admixture (42% European, 36% Amerindian, and 20% African). This is a very distinct genetic background in comparison with that of the other ethnic populations in which the association between SNPs in the microRNA genes have typically been evaluated [12].

We identified three variants with the apparent potential to influence the risk of developing ALL - the rs3805500 variant of the *DROSHA* gene, rs3746444 (MIR499A gene), and rs250590 (MIR938 gene). The differential expression of these genes and their apparent role in the development of cancer has been demonstrated in a number of previous studies [13-15]. However, a number of both internal and external environmental factors may affect the levels of gene expression, which impedes the full understanding of the role of these variants in the susceptibility of the individual to ALL, which reinforces the importance of evaluating germline polymorphisms [16, 17].

The *DROSHA* gene is a key component of the synthesis of microRNAs. This gene encodes a type III RNase, which is essential for the maturation of pri-miRNAs and pre-miRNAs [18]. We found that the homozygous mutant (AA) rs3805500 genotype is associated with a threefold increase of the development of ALL. This is the first study to report the role of this polymorphism as a risk factor of ALL, although the rs3805500 mutant has already been identified as a factor in the susceptibility of individuals to other types of leukemia [19, 20]. A GWAS study [19] found that the rs3805500 mutant A allele, in a haplotype with two

Polymorphisms in microRNA genes and the ALL risk

Table 3. Distribution of the alleles and genotypes of the polymorphisms investigated in the B-cell ALL patients, in comparison with control individuals

Genotype ID	Case (%)	Control (%)	p	Model	OR (95% CI)
<i>AGO1_rs636832</i>	75	150			
AA	8 (10.7)	14 (9.3)			
AG	34 (45.3)	67 (44.7)			AA + AG vs. GG
GG	33 (44)	69 (46)	0.163	Recessive	1.687 (0.809-3.520)
Allele A	0.333	0.316			
Allele G	0.666	0.683			
<i>DROSHA_rs10035440</i>	80	148			
TT	60 (75)	98 (66.2)			
TC	17 (21.3)	44 (29.7)			TT + TC vs. CC
CC	3 (3.8)	6 (4.1)	0.434	Recessive	2.082 (0.331-13.085)
Allele T	0.856	0.810			
Allele C	0.143	0.189			
<i>DROSHA_rs3805500</i>	74	159			
GG	11 (14.9)	50 (31.4)			
GA	26 (35.1)	51 (32.1)			GG + GA vs. AA
AA	37 (50)	58 (36.5)	0.004	Recessive	2.913 (1.415-5.998)
Allele G	0.324	0.474			
Allele A	0.675	0.525			
<i>MIR219-1_rs213210</i>	82	166			AA vs. AG + GG
AA	64 (78)	134 (80.7)	0.813	Dominant	0.908 (0.409-2.015)
AG	16 (19.5)	19 (11.4)			
GG	2 (2.4)	13 (7.8)			
Allele A	0.878	0.864			
Allele G	0.121	0.135			
<i>MIR219-1_rs107822</i>	73	152			CC vs. CT + TT
CC	36 (49.3)	85 (55.9)	0.831	Dominant	0.929 (0.471-1.832)
CT	30 (41.1)	53 (34.9)			
TT	7 (9.6)	14 (9.2)			
Allele C	0.698	0.733			
Allele T	0.301	0.266			
<i>MIR146A_rs2910164</i>	81	160			GG vs. GC + CC
GG	47 (58)	68 (42.5)	0.091	Dominant	1.777 (0.912-3.462)
GC	24 (29.6)	74 (46.3)			
CC	10 (12.3)	18 (11.3)			
Allele G	0.728	0.656			
Allele C	0.271	0.343			
<i>MIR300_rs12894467</i>	76	175			TT vs. TC + CC
TT	22 (28.9)	75 (42.9)	0.062	Dominant	0.513 (0.254-1.035)
TC	42 (55.3)	80 (45.7)			
CC	12 (15.8)	20 (11.4)			
Allele T	0.565	0.657			
Allele C	0.474	0.342			
<i>MIR499_rs3746444</i>	75	167			
AA	5 (6.7)	126 (75.4)			
AG	43 (57.3)	36 (21.6)			AA + AG vs. GG
GG	27 (36)	5 (3.0)	<0.001	Recessive	17.797 (5.55-57.016)

Polymorphisms in microRNA genes and the ALL risk

<i>Allele A</i>	0.353	0.862			
<i>Allele G</i>	0.646	0.137			
<i>MIR608_rs4919510</i>	81	161			GG vs. GC + CC
GG	5 (6.2)	18 (11.2)	0.325	Dominant	0.566 (0.182-1.760)
GC	29 (35.8)	58 (36)			
CC	47 (58)	85 (52.8)			
<i>Allele G</i>	0.240	0.291			
<i>Allele C</i>	0.759	0.708			
<i>MIR938_rs2505901</i>	76	150			CC vs. CT + TT
CC	15 (19.7)	53 (35.3)	0.013	Dominant	0.359 (0.160-0.805)
CT	38 (50)	46 (37.7)			
TT	23 (30.3)	51 (34)			
<i>Allele C</i>	0.447	0.506			
<i>Allele T</i>	0.552	0.493			

OR: Odds Ratio; CI: Confidence interval. The *p* values refer to the logistic regression adjusted for sex and Amerindian ancestry.

other polymorphisms, was associated with an increased risk of Chronic Lymphocytic Leukemia (CLL), which is consistent with our finding that the rs3805500 mutant A allele contributes to an increased susceptibility to leukemia.

Polymorphisms in the DROSHA gene may influence shared pathways in the development of both ALL and CLL [19]. The rs3805500 mutant is also in linkage disequilibrium with the rs640831 variant of the same gene, which is related to a reduction in the expression of the DROSHA mRNA, and an alteration in the maturation of pri-miRNAs and pre-miRNAs, a condition linked to the progression of a number of different types of cancer [21-25].

Another variant analyzed here is the rs3746444, which is located in the seed region of the MIR-499a-3p gene, and may impede the microRNA from binding to its targets [12, 26]. Our results indicate an association between the homozygous mutant genotype (GG) and a 17-fold increase in the risk of developing ALL. Other studies have reported an association between the rs3746444 polymorphism and susceptibility to a number of malignant neoplasia, although these findings have been controversial [27-30]. The homozygous mutant (GG) rs3746444 genotype has been related to the risk of gastric and lung cancer in Asian populations, but not in Caucasians [29, 30]. The contradictory nature of these results is probably due to the distinct genetic backgrounds of the different types of cancer and

interethnic differences between the Asian and Caucasian populations [12, 29, 30]. In the ALL, few studies have investigated the role of rs3746444 polymorphism in its development, which were carried out in homogeneous Caucasian populations [12, 26]. Hasani et al. (2014) showed no association of this variant with the risk of ALL [12], while Gutierrez-Camino (2014), described a protective effect of the G allele on the risk of ALL [26]. Further studies are needed to better elucidate the role of this variant in the ALL development. Furthermore, many findings indicate the potential influence of ethnicity in genetic associations, and reinforce the need for the analysis of ancestry to guarantee more conclusive studies.

The MIR938 gene is responsible for the regulatory pathways of the genes related to cell survival and apoptosis [31]. Variants of the SNP type present in the MIR938 gene have been associated with modifications in its biogenesis and stability [32, 33]. We investigated the rs2505901 variant, which corresponds to a C>T nucleotide swap in the intronic region of the MIR938 gene, and found that the wild homozygous (CC) genotype of this variant is associated with a 33% decrease in the risk of development of ALL. A decrease in the risk of gastric cancer was also observed in wild homozygous genotype carriers [34], which corroborates the protective effect of the rs2505901 variant. It is important to note here that only a few studies have investigated the role of this polymorphism in the development of

cancer, in general, and that the present study is the first to evaluate its role in ALL.

Chromosome abnormalities have an important role in the predisposition, prognosis, and treatment of ALL [35]. In the present study, a majority (53.57%) of the patients did not present any of the chromosomal translocations investigated. Even so, 45.24% of the translocations observed were of high or intermediate risk (BCR-ABL, E2A-PBX1, ETV6-RUNX1, MLL-AF4) [36, 37].

Conclusions

Overall, then, the present study provides convincing evidence of the influence of the rs3805500 (DROSHA), rs3746444 (MIR499), and rs2505901 (MIR938) variants on the susceptibility of the Brazilian Amazon population to ALL. From a methodological viewpoint, the use of SNPs as biomarkers is more practicable than the analysis of mRNA expression, given that germline variants can be investigated through the analysis of peripheral blood, requiring less costly laboratory procedures. Our findings are fundamental to the better understanding of the susceptibility of the population of the Brazilian Amazon region to ALL. This is an important advance, given the unique, ethnically diverse background of this population, which is quite distinct from the more homogeneous populations, which have been the focus of most previous ALL research.

Acknowledgements

We thank Antonio A.C. Modesto and R.B. Andrade, for technical assistance and we also thank all research participants, their families and the clinical staff for their skilled assistance. This research was supported by the National Council for Scientific and Technological Development (CNPq) and Pro-rector of Research and Post-graduation (Propesp) of Federal University of Pará.

Disclosure of conflict of interest

None.

Address correspondence to: Ney Pereira Carneiro dos Santos, João de Barros Barreto University Hospital-Research Center of Oncology, 2° Floor of The High Complexity Unit in Oncology, Av.

Mundurucus, 4487, Guamá, 66073-005, Belém-PA, Brazil. Tel: +55 (91) 3201-6778; (+55) 091 991139221; E-mail: npcsantos.ufpa@gmail.com

References

- [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394-424.
- [2] Ward E, DeSantis C, Robbins A, Kohler B and Jemal A. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin* 2014; 64: 83-103.
- [3] Linet MS, Brown LM, Mbulaiteye SM, Check D, Ostroumova E, Landgren A and Devesa SS. International long-term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0-19 years. *Int J Cancer* 2016; 138: 1862-1874.
- [4] Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL Consortium, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K and Houlston RS. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. *Nat Commun* 2018; 9: 1340.
- [5] International Agency for Research on Cancer Lyon. IARC monographs on the evaluation of carcinogenic risks to humans: outdoor air pollution. 109th edition. Lyon: International Agency for Research on Cancer; 2015.
- [6] Brisson GD, Alves LR and Pombo-de-Oliveira MS. Genetic susceptibility in childhood acute leukaemias: a systematic review. *Eccancermedicalsecience* 2015; 9: 539.
- [7] O'Brien J, Hayder H, Zayed Y and Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Front Endocrinol (Lausanne)* 2018; 9: 402.
- [8] Drobna M, Szarzyńska-Zawadzka B and Dawidowska M. T-cell acute lymphoblastic leukemia from miRNA perspective: basic concepts, experimental approaches, and potential biomarkers. *Blood Rev* 2018; 32: 457-472.
- [9] Santos NP, Ribeiro-Rodrigues EM, Ribeiro-Dos-Santos AK, Pereira R, Gusmão L, Amorim A, Guerreiro JF, Zago MA, Matte C, Hutz MH and

Polymorphisms in microRNA genes and the ALL risk

- Santos SE. Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. *Hum Mutat* 2010; 31: 184-190.
- [10] Ramos BR, D'Elia MP, Amador MA, Santos NP, Santos SE, da Cruz Castelli E, Witkin SS, Miot HA, Miot LD and da Silva MG. Neither self-reported ethnicity nor declared family origin are reliable indicators of genomic ancestry. *Genetica* 2016; 144: 259-265.
- [11] Pritchard JK and Donnelly P. Case-control studies of association in structured or admixed populations. *Theor Popul Biol* 2001; 60: 227-237.
- [12] Hasani SS, Hashemi M, Eskandari-Nasab E, Naderi M, Omrani M and Sheybani-Nasab M. A functional polymorphism in the miR-146a gene is associated with the risk of childhood acute lymphoblastic leukemia: a preliminary report. *Tumor Biol* 2014; 35: 219-225.
- [13] Poursadegh Zonouzi AA, Shekari M, Nejatizadeh A, Shakerizadeh S, Fardmanesh H, Poursadegh Zonouzi A, Rahmati-Yamchi M and Tozih M. Impaired expression of Drosha in breast cancer. *Breast Dis* 2017; 37: 55-62.
- [14] Wang BQ, Yang B, Yang HC, Wang JY, Hu S, Gao YS and Bu XY. MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway. *Brain Res Bull* 2018; 142: 96-106.
- [15] Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H and Allison RR. Diagnostic MicroRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. *Cancer Genomics Proteomics* 2013; 10: 93-113.
- [16] Lobo I. Environmental influences on gene expression | learn science at scitable. *Nat Educ* 2008; 1: 39.
- [17] Goldinger A, Shakhbazov K, Henders AK, McRae AF, Montgomery GW and Powell JE. Seasonal effects on gene expression. *PLoS One* 2015; 10: e0126995.
- [18] Phua SL, Sivakamasundari V, Shao Y, Cai X, Zhang LF, Lufkin T and Featherstone M. Nuclear accumulation of an uncapped RNA produced by Drosha cleavage of a transcript encoding miR-10b and Hoxd4. *PLoS One* 2011; 6: e25689.
- [19] Martin-Guerrero I, Gutierrez-Camino A, Lopez-Lopez E, Bilbao-Aldaiturriaga N, Pombar-Gomez M, Ardanaz M and Garcia-Orad A. Genetic variants in MiRNA processing genes and Pre-MiRNAs are associated with the risk of chronic lymphocytic leukemia. *PLoS One* 2015; 10: e0118905.
- [20] Hashemi M, Hasani SS and Naderi M. DROSHA rs642321 polymorphism influence susceptibility to childhood acute lymphoblastic leukemia: a preliminary report. *Indian J Med Paediatr Oncol* 2017; 38: 416-419.
- [21] López-López E, Gutiérrez-Camino Á, Piñán MÁ, Sánchez-Toledo J, Uriz JJ, Ballesteros J, García-Miguel P, Navajas A and García-Orad Á. Pharmacogenetics of MicroRNAs and MicroRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. *PLoS One* 2014; 9: e91261.
- [22] Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD and Chen J. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. *Proc Natl Acad Sci U S A* 2007; 104: 19971-19976.
- [23] Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Ando T, Mori R, Takashima N, Ogawa R and Fujii Y. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. *Clin Cancer Res* 2006; 12: 7322-7328.
- [24] Muralidhar B, Goldstein LD, Ng G, Winder DM, Palmer RD, Gooding EL, Barbosa-Morais NL, Mukherjee G, Thorne NP, Roberts I, Pett MR and Coleman N. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. *J Pathol* 2007; 212: 368-377.
- [25] Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M and Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. *N Engl J Med* 2008; 359: 2641-2650.
- [26] Gutierrez-Camino A, Lopez-Lopez E, Martin-Guerrero I, Piñán MA, Garcia-Miguel P, Sanchez-Toledo J, Carbone Bañeres A, Uriz J, Navajas A and Garcia-Orad A. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility. *Pediatr Res* 2014; 75: 767-773.
- [27] Zhang LH, Hao BB, Zhang CY, Dai XZ and Zhang F. Contributions of polymorphisms in mir146a, mir196a, and mir499 to the development of hepatocellular carcinoma. *Genet Mol Res* 2016; 9: 15.
- [28] Nouri R and Ghorbian S. Association of single nucleotide polymorphism in hsa-miR-499 and hsa-miR-196a2 with the risk of prostate cancer. *Int Urol Nephrol* 2019; 51: 811-816.
- [29] Yang X, Li X and Zhou B. A meta-analysis of miR-499 rs3746444 polymorphism for cancer

Polymorphisms in microRNA genes and the ALL risk

- risk of different systems: evidence from 65 case-control studies. *Front Physiol* 2018; 9: 737.
- [30] Wang F, Sun G, Zou Y, Li Y, Hao L and Pan F. Association of microRNA-499 rs3746444 polymorphism with cancer risk: evidence from 7188 cases and 8548 controls. *PLoS One* 2012; 7: e45042.
- [31] Wu Y, Jia Z, Cao D, Wang C, Wu X, You L, Wen S, Pan Y, Cao X and Jiang J. Predictive value of miR-219-1, miR-938, miR-34b/c, and miR-218 polymorphisms for gastric cancer susceptibility and prognosis. *Dis Markers* 2017; 2017: 4731891.
- [32] Torruella-Loran I, Ramirez Viña MK, Zapata-Contreras D, Muñoz X, Garcia-Ramallo E, Bonet C, Gonzalez CA, Sala N and Espinosa-Parrilla Y. rs12416605:C>T in miR938 associates with gastric cancer through affecting the regulation of the CXCL12 chemokine gene. *Mol Genet Genomic Med* 2019; 7: 832.
- [33] Kim WH, Min KT, Jeon YJ, Kwon C II, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG and Kim NK. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. *Gene* 2012; 504: 92-97.
- [34] Arisawa T, Tahara T, Shiroeda H, Matsue Y, Minato T, Nomura T, Yamada H, Hayashi R, Saito T, Matsunaga K, Fukuyama T, Hayashi N, Otsuka T, Fukumura A, Nakamura M and Shibata T. Genetic polymorphisms of IL17A and pri-microRNA-938, targeting IL17A 3'-UTR, influence susceptibility to gastric cancer. *Hum Immunol* 2012; 73: 747-752.
- [35] Pui CH and Evans WE. Treatment of acute lymphoblastic leukemia. *N Engl J Med* 2006; 354: 166-178.
- [36] Duque-Afonso J, Lin CH, Han K, Wei MC, Feng J, Kurzer JH, Schneidawind C, Wong SH, Bassik MC and Cleary ML. E2A-PBX1 remodels oncogenic signaling networks in B-cell precursor acute lymphoid leukemia. *Cancer Res* 2016; 76: 6937-6949.
- [37] Pui CH, Nichols KE and Yang JJ. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. *Nat Rev Clin Oncol* 2019; 16: 227-240.
- [38] Song X, Zhong H, Wu Q, Wang M, Zhou J, Zhou Y, Lu X and Ying B. Association between SNPs in microRNA machinery genes and gastric cancer susceptibility, invasion, and metastasis in Chinese Han population. *Oncotarget* 2017; 8: 86435-86446.
- [39] Dobrijević Z, Matijašević S, Savić-Pavićević D and Brajušković G. Association between genetic variants in genes encoding argonaute proteins and cancer risk: a meta-analysis. *Pathol Res Pract* 2020; 216: 152906.
- [40] Gutiérrez-Malacatt H, Ayala-Sanchez M, Aquino-Ortega X, Dominguez-Rodriguez J, Martinez-Tovar A, Olarte-Carrillo I, Martinez-Hernandez A, C CC, Orozco L and Cordova EJ. The rs61764370 functional variant in the KRAS oncogene is associated with chronic myeloid leukemia risk in women. *Asian Pac J Cancer Prev* 2016; 17: 2265-70.
- [41] López-López E, Gutiérrez-Camino Á, Piñán MÁ, Sánchez-Toledo J, Uriz JJ, Ballesteros J, García-Miguel P, Navajas A and García-Orad Á. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. *PLoS One* 2014; 9: e91261.
- [42] Zheng C, Li X, Xia L, Fang X, Quan X, Yin Z, Zhao Y and Zhou B. Polymorphisms of pri-miR-219-1 are associated with the susceptibility and prognosis of non-small cell lung cancer in a Northeast Chinese population. *Oncotarget* 2017; 8: 56533-56541.
- [43] Song X, You W, Zhu J, Cui X, Hu J, Chen Y, Liu W, Wang L, Li S, Wei Y, Yang L and Li F. A genetic variant in miRNA-219-1 is associated with risk of esophageal squamous cell carcinoma in Chinese kazakhs. *Dis Markers* 2015; 2015: 541531.
- [44] Pei JS, Chang WS, Hsu PC, Chen CC, Chin YT, Huang TL, Hsu YN, Kuo CC, Wang YC, Tsai CW, Gong CL and Bau DT. Significant association between the miR146a genotypes and susceptibility to childhood acute lymphoblastic leukemia in Taiwan. *Cancer Genomics Proteomics* 2020; 17: 175-180.
- [45] Liu Z, Lin Y, Kang S, Xu Q, Xiong W, Cai L and He F. miR-300 rs12894467 polymorphism may be associated with susceptibility to primary lung cancer in the Chinese Han population. *Cancer Manag Res* 2018; 10: 3579-3588.
- [46] He F, Lin J, Yu T, Zhang X, Liu Z, Xiong W and Cai L. Interaction research on smoking and microRNA genes SNP related to lung cancer in Fujian Han population. *Zhonghua Yu Fang Yi Xue Za Zhi* 2016; 50: 168-74.
- [47] Dai ZM, Lv JR, Liu K, Lei XM, Li W, Wu G, Liu XH, Zhu YX, Hao Q and Dai ZJ. The role of microRNA-608 polymorphism on the susceptibility and survival of cancer: a meta-analysis. *Aging (Albany NY)* 2018; 10: 1402-1414.
- [48] Liu H, Zhou Y, Liu Q, Xiao G, Wang B, Li W, Ye D and Yu S. Association of miR-608 rs4919510 polymorphism and cancer risk: a meta-analysis based on 13,664 subjects. *Oncotarget* 2017; 8: 37023-37031.

Polymorphisms in microRNA genes and the ALL risk

Table S1. References used for selection of the investigated genes and polymorphisms

GENE	Variant ID	References
<i>AGO1</i>	rs636832	[38-40]
<i>DROSHA</i>	rs10035440	[20, 41]
	rs3805500	[19-21]
<i>MIR219-1</i>	rs107822	[42, 43]
	rs213210	[31, 43]
<i>MIR146a</i>	rs2910164	[12, 44]
<i>MIR300</i>	rs12894467	[45, 46]
<i>MIR499a</i>	rs3746444	[12, 26]
<i>MIR608</i>	rs4919510	[47, 48]
<i>MIR938</i>	rs2505901	[31, 34]

Table S2. Characterization of the polymorphisms analyzed in the present study and their quality control parameters

GENE	rs	ALLELE	FUNCTION	QUALITY CONTROL			
				MAF	Genotyping rate	HWE*	Status
<i>AGO1</i>	rs636832	A>G	Intron variant	36%	80%	0.33887	Included
<i>DROSHA</i>	rs10035440	T>C	Intron variant	15%	81%	1.0000	Included
<i>DROSHA</i>	rs3805500	G>A	Intron variant	49%	83%	0.20689	Included
<i>MIR146a</i>	rs2910164	G>C	Mature miRNA variant	29%	86%	0.12694	Included
<i>MIR219-1</i>	rs213210	A>G	Regulatory region variant	17%	89%	0.02196	Included
<i>MIR219-1</i>	rs107822	C>T	TF binding site	37%	80%	0.07143	Included
<i>MIR300</i>	rs12894467	T>C	Non-coding transcript exon variant	39%	90%	0.00204	Included
<i>MIR499a</i>	rs3746444	A>G	Mature miRNA variant	18%	86%	0.11173	Included
<i>MIR608</i>	rs4919510	G>C	Mature miRNA variant	36%	86%	1.0000	Included
<i>PRE-MIR-938</i>	rs2505901	C>T	Intron variant	40%	81%	0.00859	Included

*Significance adjusted for multiple comparisons by the Bonferroni correction ($P \leq 0.001$).